Vector Model and Index for Monoclonal Antibody Clinical

Data Characteristics

Monoclonal antibody clinical trial data originates from public databases (e.g., ClinicalTrials.gov, WHO ICTRP) and pharmaceutical company internal reports, research papers, and patent literature. Data updates frequently. ClinicalTrials.gov records update daily, while research papers and patents release quarterly or annually. Document structures typically contain both structured and unstructured information. Structured parts include clear fields like trial ID, institution, indication, drug name, dosage, administration route, trial phase, primary endpoint, and secondary endpoint. Unstructured parts cover detailed trial protocol descriptions, subject inclusion/exclusion criteria, adverse event reports, and biomarker analysis results as free text. Field units involve dosage (mg/kg), time (weeks, months), and biological indicators (ng/mL, U/L).

Constraints Imposed by These Characteristics on "Vector Model and Indexing"

The multimodal nature of monoclonal antibody clinical trial data (coexistence of structured and unstructured information) requires vector models to effectively integrate different information sources. For example, detailed trial protocol descriptions (unstructured text) and trial phase, indication (structured fields) are equally important for pre-screening results. Frequent data updates demand real-time indexing, requiring support for incremental indexing or rapid full updates. Document lengths vary significantly, from detailed trial reports spanning dozens of pages to summaries of a few paragraphs. This impacts text chunking strategy development. Specifically, inclusion/exclusion criteria often appear as lists and use highly specialized language, requiring fine-grained processing to avoid semantic loss. Field and unit standardization varies, potentially introducing noise during vectorization. This necessitates normalization or entity recognition during the preprocessing stage.

Configuration Settings

Configuration Item	Suggested Value	Rationale
`Chunk size` (Chunk Size)	`512 characters`	Balances semantic completeness for long documents with retrieval accuracy for short texts, avoiding information overload in a single chunk.
`Chunk overlap` (Chunk Overlap)	`128 characters`	Retains contextual information, reducing semantic fragmentation at chunk boundaries, especially for descriptive trial protocols.
`Recall count` (Recall Count)	`Top 20 entries`	Ensures coverage, providing enough candidate results for subsequent re-ranking and filtering.
`Similarity threshold` (Similarity Threshold)	Calibrated by measurement	Balances recall and precision based on actual business needs and data distribution; start adjusting from `0.75`.
`Rerank result count` (Re-rank Return Count)	`Top 5 entries`	Reduces downstream processing burden while maintaining result quality, quickly presenting core information.
`embedding_model`	`Qwen3-Embedding`	Demonstrates good understanding of biomedical terminology, capable of capturing deep semantic meaning related to antibodies.

Common Pitfalls

Query results lack critical trial information; for example, trials with specific dosages or administration routes are not recalled. This usually happens when unstructured text is chunked too finely, causing key information to be split across different chunks, and a single chunk cannot provide complete semantics.
The vector database fails to start or reports pg_hba.conf related errors after deployment. This occurs because Milvus's Docker Compose file might integrate PostgreSQL as a metadata store, but its configuration conflicts with the current environment. Adjust the database configuration in milvus.yaml or docker-compose.yaml according to the actual deployment environment.
Pre-screening results contain a large number of irrelevant clinical trials, leading to a high false positive rate. This might be due to a Similarity threshold (Similarity Threshold) set too low, or the embedding_model inadequately understanding specialized monoclonal antibody terminology, failing to effectively distinguish highly similar but semantically different trials.

How to Verify Configuration

For queries targeting different indications, antibody targets, and trial phases, check if the recalled trial IDs include the expected highly relevant trials.
Select several trial protocols with known key information. Query based on their key fields (e.g., indication, target, drug name). Check if these trials are accurately recalled and evaluate their ranking in the recall list.
Adjust the Similarity threshold (Similarity Threshold) and observe changes in the quantity and quality of recalled results. This helps determine a threshold that balances recall and precision.
Simulate high-frequency data update scenarios. Verify that the incremental update or full rebuild process of the vector index is stable and efficient, and that query results remain consistent after updates.

The values given are common starting points and should be measured against the reader's own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.